Bayer Reaches $7.25 Billion Settlement in Roundup Cancer Lawsuits

The agrochemical company Bayer has announced a proposed $7.25 billion settlement to resolve thousands of U.S. Lawsuits alleging that its Roundup weedkiller caused cancer. The agreement, filed in St. Louis circuit court in Missouri on Tuesday, aims to address claims that Bayer failed to warn users about the potential health risks associated with Roundup’s key ingredient, glyphosate.

Settlement Details and Context

The proposed settlement comes as the U.S. Supreme Court prepares to hear arguments in a separate case concerning Bayer’s assertion that the Environmental Protection Agency’s (EPA) approval of Roundup without a cancer warning should invalidate state court claims [Reuters]. The settlement will not affect the Supreme Court case, but it aims to mitigate risk for both Bayer and plaintiffs, regardless of the court’s eventual ruling.

Bayer, which acquired Monsanto in 2018, maintains that glyphosate does not cause non-Hodgkin lymphoma. However, the company has acknowledged that mounting legal costs pose a threat to its continued sale of the product in U.S. Agricultural markets [New York Times].

Bayer’s Perspective

“Litigation uncertainty has plagued the company for years and this settlement gives the company a road to closure,” stated Bayer’s CEO, Bill Anderson [New York Times]. Anderson also described the settlement as an “important addition” to the ongoing Supreme Court case [Reuters].

Supreme Court Case and Future Outlook

The Supreme Court’s decision, expected by June 2026, could significantly impact future Roundup litigation. A favorable outcome for Bayer would further reduce the company’s legal exposure [Bayer]. The settlement is intended to complement the Supreme Court case, providing a more comprehensive resolution to the Roundup-related legal challenges.

The settlement is subject to court approval.